knowledge -WSS

knowledge

author：hotspot 2025-09-30 14:58:05 - browse：12

A liver with a smooth and healthy left half and a bumpy, browning right half — chronic disease coverage from STAT — Adobe

Akero Therapeutics said Monday that extending treatment with its experimental drug for the liver disease known as MASH from six months to two years resulted in better outcomes for patients — most notably reductions in liver scarring at a rate three times higher than placebo without worsening other symptoms.

The mid-stage study of the Akero drug called efruxifermin achieved its main goal in September 2022. With longer treatment, more patients with MASH responded to the drug, while those who initially benefited showed durable improvements.

“We’re really pleased with the data. It’s exactly what we were hoping to see,” said Kitty Yale, Akero’s chief development officer, in an interview with STAT. “It’s not just the high response rates, but the fact that responses are sustained and broadened as well.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： It was time to plan for my old age. If only I could stop crying

WSS

Many breast cancer patients receive more radiation than needed

International team creates first chimeric human

How to address the problem of discarded donor organs

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

Scientists unlock the key to scar

With heat waves through August, officials warn of health risks

Wikipedia

knowledge

focus

Medicare details structure of new drug price negotiation program

How CRISPR works, explained in two minutes

Medical records are filled with copy

Flash flood warnings continue for parts of Missouri, Illinois

United colonoscopy coverage change 'may cost lives,' doctors say

Failure, not just success, should guide future doctors

Activists slam private health insurers over coverage restrictions

Kenai launches with $82 million for Parkinson’s stem cell therapy

Affirmative action in medical school literally saved lives

McConnell is warmly embraced by Kentucky Republicans amid questions about his health

leisure time

Medical device lobby: We're tired of waiting on Medicare coverage

Pennsylvania man bitten on the head by bear during attack in his garage

Sage considers ways to reduce costs following FDA rejection

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

RSV vaccines may be linked to small increased risk of developing GBS

Russia promises retaliation after Ukrainian drones hit a Russian tanker in 2nd sea attack in a day

focus

entertainment

explore

hotspot